Cost effectiveness analysis of varenicline (champix®) for the treatment of smoking in spain;Análisis coste-efectividad de vareniclina (Champix®) en el tratamiento del tabaquismo en España

Anales de Medicina Interna

Volumn 25, Issue 7, 2008, Pages 342-348

  De Fernandez Bobadilla Osorio J ^a,b   Sanchez Maestre C ^c   Riestra, M Brosa ^d   Arroyo, O ^e   De Sanz Burgoa, V ^e   Wilson, K ^f  

^a PFIZER INC   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Euroclin Institute Madrid   (Spain)

^d Oblikue Consulting Barcelona   (Spain)

^e PFIZER

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cost effectiveness; Smoking cessation; Vareniclin

Indexed keywords

AMFEBUTAMONE; VARENICLINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NICOTINE REPLACEMENT THERAPY; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; SPAIN; TOBACCO DEPENDENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; SMOKING; SMOKING CESSATION; SPAIN; YOUNG ADULT;

EID: 63049130124     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Banegas JR, Díez Gañán L, González Enríquez J, Villar Alvarez F, Rodr guez-Artalejo F. La mortalidad atribuible al tabaquismo comienza a descender en España. Med Clin (Barc) 2005; 124: 769-71.
2. Antonanzas F, Portillo F. Evaluación económica del empleo de terapias farmacológicas para la cesación en el hábito tabáquico. Gac Sanit 2003; 17: 393-403.
3. González-Enríquez J, Salvador-Llivina T, López-Nicolas A y cols. Mor-bilidad, mortalidad y costes sanitarios evitables mediante una estrategia de tratamiento del tabaquismo en España. Gac Sanit 2002; 16: 308-17.
4. Instituto Nacional de Estadística. Proyecciones de la población española (2007). Disponible en: http://www.ine.es/ inebase/index.html.
5. Instituto Nacional de Estadística. Defunciones según la causa de muerte (2004). Disponible en: http://www.ine.es/inebase/index.html.
6. Generalitat de Catalunya. Departament de Sanitat i Seguretat Social. Enquesta de Salut de Catalunya (ESCA). Barcelona: Servei Català de la Salut; 2006.
7. Departament de Salut (Generalitat de Cataluña). Enquesta de Salut Catalunya 2006. Disponible en: http://www.gencat.cat/salut/depsan/units/sanitat/ html/ca/premsa/doc11893.html
8. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT et al. A dynamic population model of disease progression in COPD.Eur Respir J 2005; 26 (2): 223-33.
9. Sobradillo V, Miratvilles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-9.
10. Thun MJ, Glynn TJ. Health consequences of eclipse cigarettes. JAMA 2000; 284: 2995-6.
11. Parkin DM, Whelan SL, Ferlay J, Raymond L, Joung L. Incident Cancer in Five continents. Lyon: International Agency for Research on Cancer, 1997. Scientific Publication n.o 143.
12. International Agency for Research on Cancer. EUCAN 1996. Cancer Incidence, Mortality and Prevalence in the European Union. Disponible en: http://www-dep.iarc.fr/eucan.htm.
13. López-Abente G, Pollán M, Aragonés N y cols. Plan integral del cáncer. Situación del cáncer en España. Madrid: Ministerio de Sanida y Consumo; 2003.
14. Cassino C, Ito K, Bader I, Ciotoli C, Thurston G, Reibman J. Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City. Am J Respir Crit Care Med 1999; 159: 1773-9.
15. NICE. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation'. Guidance 39, March 2002. Disponible en: www.nice.uk.org
16. NICE. Guidance on the use of varenicline for smoking cessation. Guidance; 2007: 123. Disponible en: www.nice.uk.org
17. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005; 23 (6): 619-37.
18. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475-80.
19. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19: 855-63.
20. Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 2005; 23: 133-41.
21. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637.
22. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 2000; 31: 1429-38.
23. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083-91.
24. Consejo General de Colegios de Farmacéuticos. Catálogo de Especialidades Farmacéuticas; 2006. Disponible en: http://portalfarma. com.
25. Gisbert R, Brosa M. Base de Datos de Costes Sanitarios eSALUD [Base de datos en Internet]. Barcelona: Oblikue Consulting, S.L.; 2007-[acce-dido 2007] Disponible en: http://www.oblikue.com/bddcostes.
26. Gonzales D, Rennard SI, Nides M, Oncken C, Billings CB, Watsky EJ, et al. Varenicline an a4β2 nicotinic acetylcholine receptor partial agonist vs bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55
27. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
28. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine. replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2004
29. Miravitlles M, Murio C, Guerrero T y cols. Costs of chronic bronchitis and COPD. A 1-year follow-up study. Chest 2003; 123: 784-91.
30. Levy E, Gabriel S, Dinet J. The Comparative Medical Costs of Atherothrombotic Disease in European Countries. Pharmacoeconomics. 2003; 21: 651-9.
31. Hervás A, Cabasés JM, Forcén T. Costes del ictus desde la perspectiva social. Enfoque de incidencia retrospectiva con seguimiento a tres años. Rev Neurol 2006; 43: 518-25.
32. Molina J, Lumbreras G, Calvo E, Naberan K, Lobo MA y grupo del estu-dio COAX. Coste y manejo de las crisis asmáticas atendidas en atención primaria (estudio COAX). Atención Primaria 2005; 36: 6-12.
33. Borderías L, García-Ortega P, Badia X, Gambas G, Casafont J, Roset M y el Grupo Prevalair. Diagnóstico de asma alérgico y características de los pacientes con asma que acuden a las consultas de alergolog a y neumología en España. Gac San. 2006; 20: 435-41.
34. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal; 2004.
35. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Métodos para la evaluación económica de los programas de asistencia sanitaria. Ediciones Díaz de Santos S.A.; Madrid; 2005.
36. Briggs AH, Goeree R, Blackhouse G and O'Brien BJ. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308.
37. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6: 217-27.
38. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006; 6: 300.
39. Cahill K, Stead LF, Lancaster T Nicotine receptor partial agonists for smoking cessation (Review). The Cochrane Collaboration 2007
40. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tec-nología sanitaria eficiente en España? Gac San 2002; 16: 334-43.